Novel Compound Against Aggressive Breast Cancer

In September 2025, researchers from the Institute of Advanced Study in Science and Technology (IASST), Guwahati, and the Indian Institute of Technology (IIT) Guwahati announced the discovery of a new nitro-substituted organoselenium compound showing promise in combating aggressive triple-negative breast cancer.

Key Points

Compound Identified: The compound, named 4-nitro-substituted benzylic diselenide (diselenide 7), was synthesised through nucleophilic substitution of benzylic halides with selenium derivatives under controlled conditions.
Laboratory Findings: In Swiss albino mice with breast adenocarcinoma, the compound significantly reduced tumour volume, angiogenesis, and metastasis, leading to improved survival rates.
Mechanism of Action: The compound blocks the Akt/mTOR and ERK signalling pathways, induces reactive oxygen species, reduces inflammation, damages cancer cell DNA, and triggers cell death.
Therapeutic Potential: Researchers highlighted the promise of nitro-substituted organoselenium compounds as multitargeting anticancer agents, offering new avenues for treating aggressive breast cancers.